At the ASM Microbe 2026 conference, US scientific instrument manufacturer Bruker presented its growing portfolio of microbiology and infection diagnostics products, highlighting several innovations in microbial identification, sepsis diagnosis, molecular testing, and next-generation sequencing workflows.
A central focus of the exhibition was the MALDI Biotyper CA system, which has received two new FDA clinical claims. The system now features MBT Compass HT CA software, the MBT FAST Shuttle US IVD, and an FDA-cleared reference database with 549 clinically validated microbial species covering bacteria, anaerobes, and yeasts. This enables clinical laboratories to perform broader and more reliable microbial identification.
Bruker also launched several new solutions for the MALDI Biotyper RUO/GP system in the US market, including the MBT Easy T Kit and the MBT Compass HT RUO/GP v.500 database covering 5,325 species. The latest database expansion adds over 600 species, with coverage of filamentous fungi increasing by approximately 30%, addressing a significant detection challenge in microbiology. Additionally, the company introduced MBioSEQ Ridom Typer software for microbial identification and outbreak analysis workflows.
In the key area of sepsis diagnosis, Bruker is developing an innovative rapid antimicrobial susceptibility testing workflow. Combining the MALDI Biotyper CA system with the Bruker Arc automated sample preparation solution for positive blood cultures, this workflow aims to deliver faster diagnoses for critically ill patients, supporting earlier clinical decision-making.
Carla Schneider, Commercial Operations Director for the Americas in Bruker's Microbiology & Infection Diagnostics division, stated, "We believe the future of microbiology lies in integrated innovation that can deliver faster, clinically actionable diagnostic results for some of the most critical patient conditions, including sepsis." She noted that the company's US microbiology business added 140 new system placements in 2025, with consumables achieving double-digit growth, a trend continuing into 2026.
Bruker recently reported its first-quarter 2026 financial results, with revenue of $823.4 million, a 2.7% year-over-year increase, though organic revenue declined by 4.4%. The company reaffirmed its full-year 2026 revenue guidance, projecting a range of $3.57 to $3.60 billion, representing 4% to 5% growth, with organic growth of 1% to 2%. Non-GAAP earnings per share are forecasted between $2.10 and $2.15, a 15% to 17% increase. Market analysts point out that while the diagnostics business shows technological promise, Bruker overall continues to face macro challenges including soft demand from academic, government, and industrial sectors, as well as currency headwinds.
Comments